ESSANGE REAGENTS AND GENTIAN DIAGNOSTICS ANNOUNCE COLLABORATION AGREEMENT

Amsterdam / Moss, 24 June 2026

ESSANGE REAGENTS AND GENTIAN DIAGNOSTICS ANNOUNCE COLLABORATION AGREEMENT Essange Reagents (“Essange”) and Gentian Diagnostics (“Gentian”) are pleased to announce their intention to enter into a collaboration agreement. Under the partnership, Essange will contribute with its technology, materials, and intellectual property related to selected existing assays, while Gentian will allocate research and development resources to support the evaluation and development activities. The intended cooperation combines Essange's expertise in specialty immunology reagents with Gentian's capabilities in adapting assays for automated clinical chemistry platforms. Initially, the parties will focus on evaluating selected assay opportunities and exploring the transfer of existing technologies into scalable turbidimetric testing formats for global diagnostic markets.

Matti Heinonen, CEO of Gentian Diagnostics, commented: “This partnership with Essange further reinforces Gentian’s position as a trusted partner for leading IVD companies. Our expertise in developing in-demand assays to high-throughput clinical chemistry platforms enables increased scalability and broader global access to these tests.”

Klaus Gögelein, CEO of Essange Reagents, added: “We are delighted to collaborate with Gentian. The cooperation represents an important opportunity to explore the broader application of Essange's technologies and to combine the complementary strengths of both organizations in diagnostic assay development.”

Contacts Essange: Linda Burger CFO Essange Reagents L.Burger@Essange-Reagents.nl +31 20 457 0707 Gentian: Njaal Kind, Group CFO njaal.kind@gentian.no, +47 91 90 65 25

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.

About Essange Reagents Essange Reagents is a Netherlands-based developer and manufacturer of specialty immunology and haematology reagents for the global in vitro diagnostics market. The company supplies leading diagnostic organizations, laboratories, and healthcare institutions in more than 50 countries and is recognized for its expertise in niche diagnostic applications, quality-focused operations, and long-standing industry relationships. Essange operates under IVDR & ISO 13485-certified quality standards and maintains a broad portfolio of clinically relevant diagnostic reagents.

About Gentian Diagnostics Gentian Diagnostics (OSE: GENT) develops and manufactures high-quality in vitro diagnostic reagents. Gentian’s expertise and focus lie in immunoassays, specifically within infections, inflammation, and kidney disease. By converting existing and clinically relevant biomarkers to the most efficient automated, high-throughput analysers, the company contributes to cost savings and helps protect lives. Gentian is based in Moss, Norway, serving the global human and veterinary diagnostics markets.